Why is BMS Zenbexus FDA approval a multiple myeloma precedent?

Bristol Myers Squibb’s Zenbexus won accelerated FDA approval in multiple myeloma, marking the first approval for a CELMoD therapy. It also set a regulatory precedent because the decision was driven by minimal residual disease as a surrogate endpoint, rather than waiting for progression-free survival data.